How severe is CVE-2018-17538?

CVE-2018-17538 has a CVSS 3.x base score of 9.8, rated critical severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.

Is CVE-2018-17538 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (83rd percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2018-17538?

CVE-2018-17538 affects Axon Evidence Sync. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2018-17538?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its critical severity, prioritise patching exposed systems.

When was CVE-2018-17538 published?

CVE-2018-17538 was published on 2018-09-26 and last updated on 2026-06-17.

CVE-2018-17538

CVE-2018-17538 is a critical-severity vulnerability in Axon Evidence Sync with a CVSS 3.x base score of 9.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low.

Key facts

Severity: Critical (CVSS 3.x base score 9.8)
CVSS v2: 7.5
EPSS exploit prediction: 2% (83rd percentile)
Actively exploited: Not listed in CISA KEV
Affected product: Axon Evidence Sync
Published: 2018-09-26
Last modified: 2026-06-17

Description

Axon (formerly TASER International) Evidence Sync 3.15.89 is vulnerable to process injection. NOTE: the vendor's position is that this CVE is not associated with information that supports any finding of any type of vulnerability

Frequently asked questions

What is CVE-2018-17538?: Axon (formerly TASER International) Evidence Sync 3.15.89 is vulnerable to process injection. NOTE: the vendor's position is that this CVE is not associated with information that supports any finding of any type of vulnerability
How severe is CVE-2018-17538?: CVE-2018-17538 has a CVSS 3.x base score of 9.8, rated critical severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2018-17538 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (83rd percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2018-17538?: CVE-2018-17538 affects Axon Evidence Sync. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2018-17538?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its critical severity, prioritise patching exposed systems.
When was CVE-2018-17538 published?: CVE-2018-17538 was published on 2018-09-26 and last updated on 2026-06-17.

References

Affected products (1)

cpe:2.3:a:axon:evidence_sync:3.15.89:*:*:*:*:*:*:*